Department of Neurology, Stroke Center, The First Hospital of Jilin University, Jilin, China.
Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong, China.
CNS Neurosci Ther. 2024 Feb;30(2):e14634. doi: 10.1111/cns.14634.
Ischemic stroke, accounting for the majority of stroke events, significantly contributes to global morbidity and mortality. Vascular recanalization therapies, namely intravenous thrombolysis and mechanical thrombectomy, have emerged as critical interventions, yet their success hinges on timely application and patient-specific factors. This review focuses on the early phase pathophysiological mechanisms of ischemic stroke and the nuances of recanalization. It highlights the dual role of neutrophils in tissue damage and repair, and the critical involvement of the blood-brain barrier (BBB) in stroke outcomes. Special emphasis is placed on ischemia-reperfusion injury, characterized by oxidative stress, inflammation, and endothelial dysfunction, which paradoxically exacerbates cerebral damage post-revascularization. The review also explores the potential of targeting molecular pathways involved in BBB integrity and inflammation to enhance the efficacy of recanalization therapies. By synthesizing current research, this paper aims to provide insights into optimizing treatment protocols and developing adjuvant neuroprotective strategies, thereby advancing stroke therapy and improving patient outcomes.
缺血性脑卒中占脑卒中事件的大多数,对全球发病率和死亡率有重大影响。血管再通治疗,即静脉溶栓和机械取栓,已成为关键干预措施,但它们的成功取决于及时应用和患者的具体情况。本综述聚焦于缺血性脑卒中的早期病理生理机制和再通的细微差别。它强调了中性粒细胞在组织损伤和修复中的双重作用,以及血脑屏障 (BBB) 在脑卒中结果中的关键作用。特别强调了缺血再灌注损伤,其特征是氧化应激、炎症和内皮功能障碍,这在再通后反而会加剧脑损伤。本综述还探讨了靶向涉及 BBB 完整性和炎症的分子途径的潜力,以提高再通治疗的效果。通过综合当前的研究,本文旨在为优化治疗方案和开发辅助神经保护策略提供见解,从而推进脑卒中治疗并改善患者预后。